170 related articles for article (PubMed ID: 16285996)
1. Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.
Falco A; Salvati F; Vitacolonna E; Avellone G; Pinto A; Di Febbo C; Ballone E; Di Nicola M; Ciabattoni G; Davì G
Atherosclerosis; 2005 Dec; 183(2):329-35. PubMed ID: 16285996
[TBL] [Abstract][Full Text] [Related]
2. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
Santilli F; Davì G; Consoli A; Cipollone F; Mezzetti A; Falco A; Taraborelli T; Devangelio E; Ciabattoni G; Basili S; Patrono C
J Am Coll Cardiol; 2006 Jan; 47(2):391-7. PubMed ID: 16412866
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
4. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost.
Lessiani G; Vazzana N; Cuccurullo C; Di Michele D; Laurora G; Sgrò G; Di Ruscio P; Simeone E; Di Iorio P; Lattanzio S; Liani R; Ferrante E; Davì G
Thromb Haemost; 2011 Feb; 105(2):321-8. PubMed ID: 21103664
[TBL] [Abstract][Full Text] [Related]
5. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.
Kapłon-Cieślicka A; Rosiak M; Postuła M; Serafin A; Kondracka A; Opolski G; Filipiak KJ
Kardiol Pol; 2013; 71(9):893-902. PubMed ID: 24065375
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
[TBL] [Abstract][Full Text] [Related]
7. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Renda G; Tacconelli S; Capone ML; Sacchetta D; Santarelli F; Sciulli MG; Zimarino M; Grana M; D'Amelio E; Zurro M; Price TS; Patrono C; De Caterina R; Patrignani P
Clin Pharmacol Ther; 2006 Sep; 80(3):264-74. PubMed ID: 16952493
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ
Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
11. Platelet activation in patients with colorectal cancer.
Sciulli MG; Filabozzi P; Tacconelli S; Padovano R; Ricciotti E; Capone ML; Grana M; Carnevale V; Patrignani P
Prostaglandins Leukot Essent Fatty Acids; 2005 Feb; 72(2):79-83. PubMed ID: 15626589
[TBL] [Abstract][Full Text] [Related]
12. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications.
Spectre G; Arnetz L; Östenson CG; Brismar K; Li N; Hjemdahl P
Thromb Haemost; 2011 Sep; 106(3):491-9. PubMed ID: 21800009
[TBL] [Abstract][Full Text] [Related]
13. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease.
Larsen SB; Grove EL; Kristensen SD; Hvas AM
Thromb Haemost; 2013 May; 109(5):920-9. PubMed ID: 23407706
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100.
Homoncik M; Jilma B; Hergovich N; Stohlawetz P; Panzer S; Speiser W
Thromb Haemost; 2000 Feb; 83(2):316-21. PubMed ID: 10739392
[TBL] [Abstract][Full Text] [Related]
15. Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke.
Alvarez-Sabín J; Penalba A; Quintana M; Krupinski J; García-Bonilla L; Montaner J
Cerebrovasc Dis; 2009; 28(4):371-7. PubMed ID: 19641312
[TBL] [Abstract][Full Text] [Related]
16. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin.
Lattanzio S; Santilli F; Liani R; Vazzana N; Ueland T; Di Fulvio P; Formoso G; Consoli A; Aukrust P; Davì G
J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25037197
[TBL] [Abstract][Full Text] [Related]
17. Influence of triflusal on platelet activation after coronary artery bypass graft.
Prieto MA; De La Cruz JP; Del Prado MF; Sánchez de la Cuesta F
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):191-7. PubMed ID: 10759013
[TBL] [Abstract][Full Text] [Related]
18. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.
Würtz M; Grove EL; Kristensen SD; Hvas AM
Heart; 2010 Mar; 96(5):368-71. PubMed ID: 19910291
[TBL] [Abstract][Full Text] [Related]
19. Platelet antiaggregatory effect of triflusal in human whole blood.
de la Cruz JP; Pavia J; Bellido I; González MC; Sánchez de la Cuesta F
Methods Find Exp Clin Pharmacol; 1988 Apr; 10(4):273-7. PubMed ID: 3386335
[TBL] [Abstract][Full Text] [Related]
20. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
